Bladder Transitional Cell Carcinoma Stage IV

Also known as: Urothelial carcinoma bladder stage IV / Transitional cell carcinoma of the bladder stage IV

Drug	Drug Name	Drug Description
DB00441	Gemcitabine	A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.

Drug	Drug Name	Target	Type
DB00441	Gemcitabine	Ribonucleoside-diphosphate reductase large subunit	target
DB00441	Gemcitabine	UMP-CMP kinase	target
DB00441	Gemcitabine	Thymidylate synthase	target
DB00441	Gemcitabine	Cytidine deaminase	enzyme
DB00441	Gemcitabine	Deoxycytidine kinase	enzyme
DB00441	Gemcitabine	P-glycoprotein 1	transporter
DB00441	Gemcitabine	Multidrug resistance-associated protein 7	transporter
DB00441	Gemcitabine	Equilibrative nucleoside transporter 1	transporter
DB00441	Gemcitabine	DNA	target
DB00441	Gemcitabine	Sodium/nucleoside cotransporter 1	transporter
DB00441	Gemcitabine	Equilibrative nucleoside transporter 2	transporter
DB00441	Gemcitabine	Solute carrier family 28 member 3	transporter
DB00441	Gemcitabine	Thymidine kinase 2, mitochondrial	enzyme
DB00441	Gemcitabine	UMP-CMP kinase	enzyme
DB00441	Gemcitabine	Nucleoside diphosphate kinase A	enzyme

Drug	Drug Name	Phase	Status	Count
DB00958	Carboplatin	2	Completed	1
DB00441	Gemcitabine	2	Completed	1
DB11641	Vinflunine	2	Completed	1